nach oben

Erschienen in:

01.10.2019 | News item

Recent investigation results from Japan's PMDA

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Revisions to the package inserts for a number of products available in Japan are necessary based on investigations of current evidence and expert advice, says the country's PMDA. ¹ …

PMDA = Pharmaceuticals and Medical Devices Agency

Pharmaceuticals and Medical Devices Agency of Japan. Summary of Investigation Results - Osimertinib mesilate. Internet Document : [2 pages], 24 Sep 2019. Available from: URL: http://www.pmda.go.jp/files/000231586.pdf

Pharmaceuticals and Medical Devices Agency of Japan. Summary of Investigation Results - Baricitinib. Internet Document : [2 pages], 24 Sep 2019. Available from: URL: http://www.pmda.go.jp/files/000231585.pdf

Pharmaceuticals and Medical Devices Agency of Japan. Summary of Investigation Results - Fluoroquinolones and quinolones (oral and injectable dosage forms). Internet Document : [15 pages], 24 Sep 2019. Available from: URL: http://www.pmda.go.jp/files/000231587.pdf

Titel: Recent investigation results from Japan's PMDA
Publikationsdatum: 01.10.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-68760-y

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Recent investigation results from Japan's PMDA

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Propofol/sevoflurane

Azathioprine

Cyclophosphamide

Erlotinib

Antineoplastics/immunosuppressants

Norepinephrine